Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells

Li,Jixia; Lin,Bihua; Li,Xiangyong; Tang,Xudong; He,Zhiwei; Zhou,Keyuan

doi:10.3892/or.2014.3639

Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells

Authors:
- Jixia Li
- Bihua Lin
- Xiangyong Li
- Xudong Tang
- Zhiwei He
- Keyuan Zhou
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Guangdong Medical College, Dongguan, Guangdong 523808, P.R. China, Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Guangdong Medical College, Dongguan, Guangdong 523808, P.R. China
Published online on: December 2, 2014 https://doi.org/10.3892/or.2014.3639
Pages: 951-957

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The epidermal growth factor receptor (EGFR) family is reportedly overexpressed in bladder cancer, and tyrosine kinase inhibitors (TKIs) have been suggested as treatment. Gefitinib (Iressa®) is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor). Both compounds compete with the binding of ATP to the tyrosine kinase domain of the respective receptors to inhibit receptor autophosphorylation causing suppression of signal transduction. Unfortunately, resistance to these inhibitors is a major clinical issue. The purpose of the present study was to use protein array analysis to compare the signaling pathway(s) induced by gefitinib and lapatinib, in UM-UC-5 (drug-sensitive) and UM-UC-14 (drug-resistant) bladder cancer cells and to identify molecular markers that may be useful predictors of their efficacy. The results revealed that phosphorylation of EGFR, HER3, Met and ERK1/2 was markedly overexpressed in the sensitive cell line (UM-UC-5) and was strongly inhibited by the TKIs. Other notable differences included decreased phosphorylation of RSK, GSK3, AMPK, Akt and c-Jun by TKIs in the sensitive cells. In contrast, phosphorylated p53 was highly expressed in the resistant cell line (UM-UC-14) and TKIs had no effect in the resistant cells. Overall results suggest that phosphorylated HER3, ERK1/2 and p53 may be used as biomarkers to determine the sensitivity of bladder cancers to TKIs. In particular, a combination of these markers may be more likely to predict the sensitivity to TKIs.

View Figures

View References

1	van Rhijn BW, Burger M, Lotan Y, et al: Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009. View Article : Google Scholar : PubMed/NCBI
2	McHugh LA, Sayan AE, Mejlvang J, et al: Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol. 34:1155–1163. 2009.PubMed/NCBI
3	Wang X, Zhang S, MacLennan GT, et al: Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 13:953–957. 2007. View Article : Google Scholar : PubMed/NCBI
4	Shrader M, Pino MS, Brown G, et al: Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 6:277–285. 2007. View Article : Google Scholar : PubMed/NCBI
5	Johnson LN: Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys. 42:1–40. 2009. View Article : Google Scholar : PubMed/NCBI
6	McHugh LA, Kriajevska M, Mellon JK and Griffiths TR: Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens - evidence of schedule-dependent synergy. Urology. 69:390–394. 2007. View Article : Google Scholar : PubMed/NCBI
7	Shrader M1, Pino MS, Lashinger L, et al: Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67:1430–1435. 2007. View Article : Google Scholar : PubMed/NCBI
8	Dancey JE and Freidlin B: Targeting epidermal growth factor receptor - are we missing the mark? Lancet. 362:62–64. 2003. View Article : Google Scholar : PubMed/NCBI
9	Xu L, Hausmann M, Dietmaier W, et al: Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer. 10:3022010. View Article : Google Scholar : PubMed/NCBI
10	Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
11	Laurent-Puig P, Lievre A and Blons H: Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res. 15:1133–1139. 2009. View Article : Google Scholar : PubMed/NCBI
12	Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar
13	Villares GJ, Zigler M, Blehm K, et al: Targeting EGFR in bladder cancer. World J Urol. 25:573–579. 2007. View Article : Google Scholar : PubMed/NCBI
14	Memon AA, Sorensen SB and Nexo E: The epidermal growth factor family has a dual role in deciding the fate of cancer cells. Scand J Clin Lab Invest. 66:623–630. 2006. View Article : Google Scholar : PubMed/NCBI
15	Memon AA, Sorensen BS, Melgard P, et al: Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer. 91:2034–2041. 2004. View Article : Google Scholar : PubMed/NCBI
16	Memon AA, Sorensen BS, Meldgaard P, et al: The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer. 94:1703–1709. 2006.PubMed/NCBI
17	Amin DN, Campbell MR and Moasser MM: The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 21:944–950. 2010. View Article : Google Scholar : PubMed/NCBI
18	Engelman JA, Jänne PA, Mermel C, et al: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA. 102:3788–3793. 2005. View Article : Google Scholar : PubMed/NCBI
19	Koutras AK, Fountzilas G, Kalogeras KT, et al: The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol. 74:73–78. 2010. View Article : Google Scholar
20	Fontana D, Bellina M, Scoffone C, et al: Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol. 29:470–476. 1996.PubMed/NCBI
21	Przybojewska B, Jagiello A and Jalmuzna P: H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet. 121:73–77. 2000. View Article : Google Scholar : PubMed/NCBI
22	Rose A, Grandoch M, vom Dorp F, et al: Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol. 160:1690–1698. 2010. View Article : Google Scholar : PubMed/NCBI
23	Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A and Spandidos DA: Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett. 107:241–247. 1996. View Article : Google Scholar : PubMed/NCBI
24	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zhang Z, Zhou X, Shen H, et al: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 7:412009. View Article : Google Scholar : PubMed/NCBI
26	Proctor I, Stoeber K and Williams GH: Biomarkers in bladder cancer. Histopathology. 57:1–13. 2010. View Article : Google Scholar : PubMed/NCBI
27	MacLaine NJ, Wood MD, Holder JC, et al: Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol Cancer Res. 6:53–63. 2008. View Article : Google Scholar : PubMed/NCBI
28	Rho JK, Choi YJ, Ryoo BY, et al: p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 67:1163–1169. 2007. View Article : Google Scholar : PubMed/NCBI
29	Stoner CS, Pearson GD, Koç A, et al: Effect of thioredoxin deletion and p53 cysteine replacement on human p53 activity in wild-type and thioredoxin reductase null yeast. Biochemistry. 48:9156–9169. 2009. View Article : Google Scholar : PubMed/NCBI